



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

08 June 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

Important notices

- Request for Information: Antimicrobial Resistance Rapid, Point-of-Care Diagnostic Test Challenge ([NOT-OD-15-104](#))
- Notice of Corrections to RFA-AI-15-029 "Martin Delaney Collaboratories for HIV Cure Research (UM1)" ([NOT-AI-15-037](#))
- Broad Agency Announcement (BAA): Staged Vaccine Development (SVD), NIAID-DAIDS-NIH-AI-2015040 ([NOT-AI-15-039](#))
- Request for Proposals (RFP) Announcement: NIAID Process and Analytical Support for Development of HIV Vaccines, NIAID-DAIDS-NIHAI2014013 ([NOT-AI-15-040](#))

1. Title: Partnerships for the Development of Host-Targeted Therapeutics to Limit Antimicrobial Resistance

Letter of Intent due date: August 17, 2015

Hyperlink: ([RFA-AI-15-024](#))

Type: RO1

Application Due Date: September 17, 2015, by 5:00 PM local time of applicant organization.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of candidate therapeutics that target host-encoded functions required for infection, replication, virulence, proliferation and/or pathogenesis of select bacterial pathogens for which drug resistance poses a significant public health concern.

Budget: Budgets for direct costs of up to \$750,000 per year may be requested. Applicants may also request up to an additional \$300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling \$1,050,000 direct costs. Consortium F&A is not included in the direct cost limitation. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Title: Adherence Studies in Adolescents with Chronic Kidney or Urologic Diseases

Letter of Intent due date: October 2, 2015

Hyperlink: ([RFA-DK-15-017](#))

Type: RO1

Application Due Date: November 2, 2015, by 5:00 PM local time of applicant organization.

Purpose: Adherence to a prescribed treatment regimen, including medications, devices and behavioral recommendations, can significantly impact morbidity and mortality for patients with chronic diseases, including chronic kidney or urologic disease. When adherence to complex and seemingly rigid treatment regimens is poor, the results can be tragic. Adolescence is a particularly challenging time for adherence given the competing demands in an adolescent's life, the unique developmental changes, and rapidly changing set of responsibilities as they transition to adulthood. There are few studies in pediatrics beyond the HIV literature that address non-adherence. The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve adherence in adolescents with chronic kidney or urologic diseases. Therefore, this Funding Opportunity Announcement (FOA) invites applications from new or established investigators to pursue research to better understand factors that influence adherence, develop appropriate measures of adherence, and test innovative strategies to enhance adherence in this vulnerable population.

Budget: Direct costs are limited to \$450,000 per year. The maximum project period is five years.

3. Title: Understanding HIV Persistence in

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: ([PA-15-271](#))

Type: RO1

Application Due Date: Standard AIDS dates apply, by 5:00 PM local time of applicant organization September 7, 2015 & January 7, 2016

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs. The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.



4. Title: Dimensional Approaches to Research Classification in Psychiatric Disorders**Letter of Intent due date:** September 9, 2015**Hyperlink:** [\(RFA-MH-16-510\)](#) **Type** RO1**Application Due Date:** October 9, 2015, by 5:00 PM local time of applicant organization.

Purpose: This Funding Opportunity Announcement (FOA) seeks research grant applications designed to develop innovative ways of understanding mental disorders in clinical studies on the basis of experimental research criteria rather than traditional diagnostic categories. This FOA stems from the NIMH Research Domain Criteria (RDoC) project that is intended to further a long-range goal of contributing to diagnostic systems as informed by research on genetics, neuroscience, and behavior. The purpose of this FOA is to encourage applications to study mechanisms that may cut across multiple traditional diagnostic categories. Applications submitted in response to this FOA should be based upon RDoC criteria (see <http://www.nimh.nih.gov/research-funding/rdoc.shtml>). Five organizing domains have been identified. These are Negative Valence Systems (i.e., aversive motivational dimensions), Positive Valence Systems, Cognitive Systems, Social Process Systems, and Arousal/Regulatory Systems. Consensus workshops and guidance documents on these five domains have been completed and applications must focus on at least one of the constructs that have been defined in these RDoC workshops. For additional information, as indicated in Section I, see the workshop proceedings posted at <http://www.nimh.nih.gov/research-priorities/rdoc/detailed-description-of-the-rdoc-project.shtml>

Budget: Application budgets are limited to \$400,000 in annual direct costs. The scope of the proposed project should determine the project period. The maximum period is 5 years.

5. Title: Understanding HIV Persistence in**Letter of Intent due date:** 30 days prior to the application due date**Hyperlink:** [\(PA-15-271\)](#) **Type** RO1**Application Due Date:** Standard AIDS dates apply, by 5:00 PM local time of applicant organization September 7, 2015 & January 7, 2016

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant's evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs. The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

6. Title: Exploiting RNA as a Target for HIV Interventions**Letter of Intent due date:** N/A**Hyperlink:** [\(PA-15-272\)](#) **Type** R21**Application Due Date:** Standard AIDS dates apply, by 5:00 PM local time of applicant organization Sep 7, 2015, Jan 7, 2016; May 7, 2016

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to: (1) investigate the role of viral and cellular long non-coding RNAs (lncRNAs) in the regulation of HIV replication, pathogenesis, latency, immunity, and gene expression; (2) exploit lncRNAs for the development of novel HIV interventions; and (3) exploit advances in RNA structural biology to identify novel targets for HIV intervention and functional cure.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years.

7. Title: Harnessing Big Data to Halt HIV**Letter of Intent due date:** 30 days prior to the application due date**Hyperlink:** [\(PA-15-273\)](#) **Type** R01**Application Due Date:** Standard AIDS dates apply, by 5:00 PM local time of applicant organization Sep 7, 2015, Jan 7, 2016; May 7, 2016

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). These approaches should include projects to assemble big data sources, conduct robust and reproducible analyses, and create meaningful visualization of big data.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Dr Christa de Vries* • Tel: 9838 • Email: cdevries@sun.ac.za